

03/07/02  
JCS60 U.S. PRO10091458  
03/07/02  
JCS60 U.S. PROPlease type a plus sign (+) inside this box → PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

*Attorney Docket* PTZ06C1

First Inventor Rosen et al.

Title Nucleic Acids, Proteins, and Antibodies

Express Mail Label

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)

2.  Applicant claims small entity status.  
See 37 CFR 1.27.

3.  Specification [Total Pages 433]

(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4.  Drawing(s) (35 U.S.C. 113) [Total Sheets ]

5. Oath or Declaration [Total Pages 5]

a.  Newly executed (original or copy)

b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)

i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 CFR 1.63(d)(2) and 1.33(b)

6.  Application Data Sheet. See 37 CFR 1.76 (7 pages)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: 09/764,900

Prior application information: Examiner Sheinberg, M. Group / Art Unit: 1631

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

**19. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label

22195

or  Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type) Mark J. Hyman Registration No. (Attorney/Agent) 46,789

Signature

Date March 7, 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Application claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** **(\$)** **896.00**

### Complete if Known

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Rosen et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	PTZ06C1

### METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  Other  None  
 Deposit Account

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

The Commissioner is hereby authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

### FEE CALCULATION (continued)

#### 3. ADDITIONAL FEES

##### Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge – late filing fee or oath	
127	50	227	25	Surcharge – late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive – unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(h))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

**SUBTOTAL (1)** **(\$)** **740.00**

#### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims	Fee from below	Fee Paid
24	-20** = 4 x 18.00 = 72.00	
4	-3** = 1 x 84.00 = 84.00	
Multiple Dependent		

#### Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2)** **(\$)** **156.00**

\*\* or number previously paid, if greater; For Reissues, see above


\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** **(\$)** **0.00**

#### SUBMITTED BY

Complete (if applicable)

Name (Print/Type) **Mark J. Hyman** Registration No. **46,789** Telephone **(240) 314-1224**

Signature  Date **March 7, 2002**

VIA HAND DELIVERY MARCH 7, 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Rosen et al.

Attorney Docket No.: PTZ06C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

**TRANSMITTAL AND SUBMISSION UNDER  
37 C.F.R. §§ 1.824 AND 1.52(e)**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer readable format requirements on a compact disc (CD-R) labeled "CRF." Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-R). Applicants certify under 37 C.F.R. § 1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, each contain the file "PTZ06C1\_seqList.txt" (105,077 bytes in size, created March 6, 2002).

Respectfully submitted,

Dated: March 7, 2002

  
Mark J. Hyman  
Attorney for Applicants

Reg. No. 46,789

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (240) 314-1224

Enclosures

VIA HAND DELIVERY MARCH 7, 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Rosen et al.

Attorney Docket No.: PTZ06C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies


**STATEMENT UNDER 37 C.F.R. § 1.821**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on compact disc) Sequence Listing submitted herewith.

Respectfully submitted,



Mark J. Hyman  
Attorney for Applicants

Reg. No. 46,789

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (240) 314-1224

Enclosures